US 12,168,691 B2
VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
Zhen Fan, Houston, TX (US); Yang Lu, Houston, TX (US); and Songho Qiu, Houston, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Appl. No. 17/058,414
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
PCT Filed May 31, 2019, PCT No. PCT/US2019/034836
§ 371(c)(1), (2) Date Nov. 24, 2020,
PCT Pub. No. WO2019/232323, PCT Pub. Date Dec. 5, 2019.
Claims priority of provisional application 62/678,733, filed on May 31, 2018.
Prior Publication US 2021/0198370 A1, Jul. 1, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/04 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/04 (2018.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01)] 4 Claims
 
1. A bispecific antibody comprising an anti-human vascular endothelial growth factor (VEGF) IgG antibody linked to an anti-human epidermal growth factor receptor-2 (HER2) scFv, wherein the VH domain of the IgG antibody is linked to the VH domain of the scFv, wherein the bispecific antibody comprises a first domain comprising SEQ ID NO:3 and a second domain comprising SEQ ID NO:4.